ABSTRACT
Hyperhomocysteinemia is recognized as risk factor for cardiovascular and age-associated diseases. Folic acid supplementation efficiently lowers plasma homocysteine (Hcy) levels, but high intake may negatively affect health because of unnatural levels of unmetabolized folic acid in the systemic circulation. Oxoproline (Oxo) provides by glutamic acid production an increase of intracellular folic acid trapping. Aim of this study was to compare the efficacy of three supplementation protocols: (1) traditional therapy (5-methyl-tetrahydrofolate: 15 mg/day); (2) 5 mL/day of Oxo with 300 µg folic acid (oxifolic); (3) 5 mL/day of Oxo alone (magnesio+) in a 90 days randomized trial on thirty-two moderate hyperhomocysteinemic (18.6 ± 2.4 µmol.L-1) patients (age 48 ± 14 yrs). Thiols: cysteine (Cys), cysteinylglycine (Cys-Gly) and glutathione levels were assessed too. Every supplementation induced significant (p range <0.05-0.0001) reductions of Hcy level and Cys concentration after the three protocols adopted. Otherwise glutathione concentration significantly increased after oxifolic (p < 0.01) and traditional (p < 0.05) supplementation. The integration of Oxo resulted an interesting alternative to traditional therapy because absence or minimal number of folates in the integrator eliminates any chance of excess that can constitute a long-term risk.
Subject(s)
Dietary Supplements , Folic Acid/administration & dosage , Hyperhomocysteinemia/therapy , Proline/administration & dosage , Tetrahydrofolates/administration & dosage , Adult , Aged , Cysteine/blood , Dipeptides/blood , Female , Folic Acid/blood , Glutathione/blood , Humans , Hyperhomocysteinemia/blood , Male , Middle Aged , Proline/analogs & derivatives , Treatment OutcomeABSTRACT
Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.
Subject(s)
Antidepressive Agents/pharmacokinetics , Dipeptides/pharmacokinetics , Administration, Oral , Animals , Antidepressive Agents/blood , Area Under Curve , Biological Availability , Dipeptides/blood , Drug Evaluation, Preclinical , Male , Rabbits , TabletsABSTRACT
Recent evidence suggests that increased brain serotonin synthesis impairs performance in high-intensity intermittent exercise and specific amino acids may modulate this condition, delaying fatigue. This study investigated the effects of glutamine and alanine supplementation on central fatigue markers in rats submitted to resistance training (RT). Wistar rats were distributed in: sedentary (SED), trained (CON), trained and supplemented with alanine (ALA), glutamine and alanine in their free form (G + A), or as dipeptide (DIP). Trained groups underwent a ladder-climbing exercise for eight weeks, with progressive loads. In the last 21 days, supplementations were offered in water with a 4% concentration. Albeit without statistically significance difference, RT decreased liver glycogen, and enhanced the concentrations of plasma glucose, free fatty acids (FFA), hypothalamic serotonin, and ammonia in muscle and the liver. Amino acids affected fatigue parameters depending on the supplementation form. G + A prevented the muscle ammonia increase by RT, whereas ALA and DIP augmented ammonia and glycogen concentrations in muscle. DIP also increased liver ammonia. ALA and G + A reduced plasma FFA, whereas DIP increased this parameter, free tryptophan/total tryptophan ratio, hypothalamic serotonin, and the serotonin/dopamine ratio. The supplementations did not affect physical performance. In conclusion, glutamine and alanine may improve or impair central fatigue markers depending on their supplementation form.
Subject(s)
Alanine/pharmacology , Fatigue/drug therapy , Glutamine/pharmacology , Physical Conditioning, Animal , Ammonia/metabolism , Animals , Blood Glucose/metabolism , Dietary Supplements , Dipeptides/blood , Dopamine/blood , Fatigue/blood , Fatty Acids, Nonesterified/blood , Glycogen/metabolism , Liver/drug effects , Liver/metabolism , Male , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Rats , Rats, Wistar , Serotonin/bloodABSTRACT
Collagen hydrolysate is a well-known dietary supplement for the treatment of skin aging; however, its mode of action remains unknown. Previous studies have shown that the oral ingestion of collagen hydrolysate leads to elevated levels of collagen-derived peptides in the blood, but whether these peptides reach the skin remains unclear. Here, we analyzed the plasma concentration of collagen-derived peptides after ingestion of high tripeptide containing collagen hydrolysate in humans. We identified 17 types of collagen-derived peptides transiently, with a particular enrichment in Gly-Pro-Hyp. This was also observed using an in vivo mouse model in the plasma and skin, albeit with a higher enrichment of Pro-Hyp in the skin. Interestingly, this Pro-Hyp enrichment in the skin was derived from Gly-Pro-Hyp hydrolysis, as the administration of pure Gly-Pro-Hyp peptide led to similar results. Therefore, we propose that functional peptides can be transferred to the skin by dietary supplements of collagen.
Subject(s)
Collagen/chemistry , Collagen/metabolism , Dipeptides/metabolism , Oligopeptides/metabolism , Protein Hydrolysates/metabolism , Skin/metabolism , Adult , Animals , Dipeptides/blood , Eating , Female , Humans , Hydrolysis , Male , Mice , Mice, Inbred BALB C , Oligopeptides/blood , Protein Hydrolysates/chemistry , Young AdultABSTRACT
BACKGROUND: The nonessential amino acid cysteine is known to be involved in many antioxidant and anticarcinogenic pathways. Cysteinylglycine is a pro-oxidant metabolite of glutathione and a precursor of cysteine. OBJECTIVE: To examine the relation between serum cysteine and cysteinylglycine and risk of gastric adenocarcinomas, esophageal squamous cell carcinomas, and head and neck squamous cell carcinomas, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention study of male Finnish smokers aged 50-69 y at baseline. DESIGN: In total, 170 gastric adenocarcinomas, 68 esophageal squamous cell carcinomas, and 270 head and neck squamous cell carcinomas (identified from the Finnish Cancer Registry) were matched one-to-one with cancer-free control subjects on age and the date of serum collection. We calculated ORs and 95% CIs with the use of a multivariate-adjusted conditional logistic regression. RESULTS: Cysteine had a U-shaped association with gastric adenocarcinomas; a model that included a linear and a squared term had a significant global P-test (P = 0.036). Serum cysteinylglycine was inversely associated with adenocarcinomas of the gastric cardia (OR for above the median compared with below the median: 0.07; 95% CI: 0.01, 0.70; n = 38 cases) but not for other sites. Both cysteine and cysteinylglycine were not associated with esophageal squamous cell carcinoma or head and neck squamous cell carcinoma. CONCLUSIONS: We observed associations between serum cysteine and cysteinylglycine with upper gastrointestinal cancer risk. Future studies are needed to replicate these findings. This trial was registered at clininicaltrials.gov as NCT00342992.
Subject(s)
Adenocarcinoma/etiology , Cysteine/blood , Deficiency Diseases/physiopathology , Dipeptides/blood , Hyperhomocysteinemia/physiopathology , Smoking/adverse effects , Stomach Neoplasms/etiology , Adenocarcinoma/blood , Adenocarcinoma/epidemiology , Adenocarcinoma/prevention & control , Antioxidants/therapeutic use , Biomarkers/blood , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/prevention & control , Case-Control Studies , Cohort Studies , Cysteine/deficiency , Deficiency Diseases/etiology , Dietary Supplements , Finland/epidemiology , Head and Neck Neoplasms/blood , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/etiology , Head and Neck Neoplasms/prevention & control , Humans , Hyperhomocysteinemia/etiology , Incidence , Male , Middle Aged , Oxidative Stress , Prospective Studies , Randomized Controlled Trials as Topic , Registries , Risk Factors , Stomach Neoplasms/blood , Stomach Neoplasms/epidemiology , Stomach Neoplasms/prevention & controlABSTRACT
Alcohol is a known carcinogen that may be associated with colorectal cancer. However, most epidemiologic studies assess alcoholic beverage consumption using self-reported data, leading to potential exposure misclassification. Biomarkers of alcohol consumption may provide an alternative, complementary approach that reduces misclassification and incorporates individual differences in alcohol metabolism. Therefore, we evaluated the relationship between previously identified alcohol consumption-related metabolites and colorectal cancer and adenoma using serum metabolomics data from two studies. Data on colorectal cancer were obtained from a nested case-control study of 502 US adults (252 cases, 250 controls) within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Data on colorectal adenoma were obtained from a case-control study of 197 US adults (120 cases, 77 controls) from the Navy Colon Adenoma Study. Unconditional multivariable logistic regression models were fit to calculate odds ratios (OR) and 95% confidence intervals (CI) for eight alcohol consumption-related metabolites identified in a previous analysis: ethyl glucuronide; 4-androstene-3beta,17beta-diol disulfate 1; 5-alpha-androstan-3beta,17beta-diol disulfate; 16-hydroxypalmitate; bilirubin (E,Z or Z,E); cyclo (-leu-pro); dihomo-linoleate (20:2n6); and palmitoleate (16:1n7). We found no clear association between these alcohol consumption-related metabolites and either endpoint. However, we did observe an inverse association between cyclo (-leu-pro) and colorectal adenoma that was only observed in the highest metabolite quantile (OR 4th vs. 1st Quantile = 0.30, 95% CI: 0.12-0.78; P-trend = 0.047), but no association for colorectal cancer. In conclusion, there were no adverse associations between alcohol consumption-related metabolites and colorectal cancer or adenoma.
Subject(s)
Adenoma/blood , Alcohol Drinking/adverse effects , Alcoholic Beverages/adverse effects , Colorectal Neoplasms/blood , Ethanol/metabolism , Aged , Androstane-3,17-diol/analogs & derivatives , Androstane-3,17-diol/blood , Bilirubin/blood , Biomarkers/blood , Case-Control Studies , Dipeptides/blood , Fatty Acids, Monounsaturated/blood , Female , Glucuronates/blood , Humans , Linoleic Acid/blood , Male , Middle Aged , Odds Ratio , Palmitic Acids/blood , Peptides, Cyclic/bloodABSTRACT
Dietary fat supplementation during the periparturient period is one strategy to increase energy intake and attenuate the degree of negative energy balance during early lactation; however, little is known of the underlying hormonal and metabolic adaptations. We evaluated the effects of prepartum fat supplementation on energy-balance parameters and plasma concentrations of glucagon-like peptide-1, peptide tyrosine-tyrosine (PYY), adropin, insulin, leptin, glucose, nonesterified fatty acid, and ß-hydroxybutyric acid in dairy cows. Twenty-four pregnant dairy cows were randomized to diets containing either rolled canola or sunflower seed at 8% of dry matter, or no oilseed supplementation, during the last 5 wk of gestation and then assigned to a common lactation diet postpartum. Blood samples were collected at -2, +2, and +14 h relative to feeding, at 2 wk after the initiation of the diets, and at 2 wk postpartum. Dietary canola and sunflower supplementation alone did not affect energy balance, body weight, and plasma concentrations of glucagon-like peptide-1, PYY, adropin, insulin, leptin, nonesterified fatty acid, and ß-hydroxybutyric acid; however, canola decreased and sunflower tended to decrease dry matter intake. We also observed that the physiological stage had a significant, but divergent, effect on circulating hormones and metabolite concentrations. Plasma glucagon-like peptide-1, PYY, adropin, nonesterified fatty acid, and ß-hydroxybutyric acid concentrations were greater postpartum than prepartum, whereas glucose, insulin, leptin, body weight, and energy balance were greater prepartum than postpartum. Furthermore, the interaction of treatment and stage was significant for leptin and adropin, and tended toward significance for PYY and insulin; only insulin exhibited an apparent postprandial increase. Postpartum PYY concentrations exhibited a strong negative correlation with body weight, suggesting that PYY may be associated with body weight regulation during the transition period. These novel findings demonstrate that the transition from pregnancy to lactation is a stronger determinant of circulating gut hormone concentrations than dietary lipid in transition dairy cows.
Subject(s)
Cattle/physiology , Dietary Fats/pharmacology , Dietary Supplements , Hormones/blood , 3-Hydroxybutyric Acid/blood , Animals , Blood Proteins/analysis , Body Weight , Cattle/blood , Diet/veterinary , Dietary Fats/administration & dosage , Dipeptides/blood , Energy Intake , Energy Metabolism , Fatty Acids, Nonesterified/blood , Female , Glucagon-Like Peptide 1/blood , Insulin/blood , Lactation , Leptin/blood , Peptide YY/blood , Postpartum Period , Pregnancy , Random AllocationABSTRACT
SCOPE: The basic dipeptide, Trp-His, was found to show an in vivo anti-atherosclerotic effect when orally administered to apo E-deficient mice. In addition, this dipeptide causes vasorelaxation in contracted rat aorta via suppression of intracellular Ca(2+) signaling cascades. In this study, we attempted to determine whether Trp-His can be absorbed after single oral administration in Sprague-Dawley (SD) rats. METHODS AND RESULTS: Trp-His and His-Trp (10 or 50 mg/kg) was orally administered to 8-week-old male SD rats. Both peptides in plasma were assayed by LC-MS/MS in combination with 2,4,6-trinitrobenzene sulfonate derivatization technique. In vitro transport experiments using Caco-2 cell monolayers were performed to evaluate the apparent permeability (Papp ). A phytic acid-aided MALDI-MS imaging (MSI) was conducted to visualize the distribution of dipeptides in the rat intestinal membrane. Trp-His was absorbed intact into SD rat blood, showing a maximal level at 1 h after administration at 10 mg/kg dose (Cmax , 28.7 ± 8.9 pmol/mL-plasma; area under the curve, 71.3 ± 18.7 pmol·h/mL-plasma). In contrast, His-Trp was surprisingly not detected, although the Papp was compatible to that of Trp-His. MSI analysis provided crucial evidence that Trp-His was visualized in the overall intestinal membrane. The Trp-His peptide was not visualized in the presence of Gly-Sar, which is a model peptide that is transported via the intestinal proton-coupled peptide transporter 1 (PepT1) transporter. The His-Trp molecular ion was not observed at the intestinal membrane. The MSI analysis illustrated that there is no absorption of His-Trp due to its unexpected hydrolysis by brush border proteases. CONCLUSION: To the best of our knowledge, this is the first study demonstrating that the vasoactive Trp-His is preferably transported across the rat intestinal membrane by PepT1 and is absorbed intact into the circulation. However, no absorption of His-Trp, a reverse sequence of absorbable Trp-His, is observed owing to hydrolysis by intestinal proteases. This suggests that the bioavailability of peptides may be determined in part by their protease resistance in the intestinal membrane.
Subject(s)
Dietary Supplements , Dipeptides/metabolism , Intestinal Absorption , Intestinal Mucosa/metabolism , Symporters/metabolism , Vasodilator Agents/metabolism , Analytic Sample Preparation Methods , Animals , Atherosclerosis/prevention & control , Caco-2 Cells , Cell Membrane Permeability , Chromatography, High Pressure Liquid , Dipeptides/administration & dosage , Dipeptides/blood , Dipeptides/chemistry , Humans , Indicators and Reagents/chemistry , Intestinal Mucosa/cytology , Male , Peptide Transporter 1 , Phytic Acid/chemistry , Rats, Sprague-Dawley , Spectrometry, Mass, Electrospray Ionization , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Tandem Mass Spectrometry , Trinitrobenzenesulfonic Acid/chemistry , Vasodilator Agents/administration & dosage , Vasodilator Agents/blood , Vasodilator Agents/chemistryABSTRACT
INTRODUCTION: Low plasma glutamine levels are associated with worse clinical outcome. Intravenous glutamine infusion dose- dependently increases plasma glutamine levels, thereby correcting hypoglutaminemia. Glutamine may be transformed to glutamate which might limit its application at a higher dose in patients with severe traumatic brain injury (TBI). To date, the optimal glutamine dose required to normalize plasma glutamine levels without increasing plasma and cerebral glutamate has not yet been defined. METHODS: Changes in plasma and cerebral glutamine, alanine, and glutamate as well as indirect signs of metabolic impairment reflected by increased intracranial pressure (ICP), lactate, lactate-to-pyruvate ratio, electroencephalogram (EEG) activity were determined before, during, and after continuous intravenous infusion of 0.75 g L-alanine-L-glutamine which was given either for 24 hours (group 1, n = 6) or 5 days (group 2, n = 6) in addition to regular enteral nutrition. Lab values including nitrogen balance, urea and ammonia were determined daily. RESULTS: Continuous L-alanine-L-glutamine infusion significantly increased plasma and cerebral glutamine as well as alanine levels, being mostly sustained during the 5 day infusion phase (plasma glutamine: from 295 ± 62 to 500 ± 145 µmol/ l; brain glutamine: from 183 ± 188 to 549 ± 120 µmol/ l; plasma alanine: from 327 ± 91 to 622 ± 182 µmol/ l; brain alanine: from 48 ± 55 to 89 ± 129 µmol/ l; p < 0.05, ANOVA, post hoc Dunn's test). CONCLUSIONS: High dose L-alanine-L-glutamine infusion (0.75 g/ kg/ d up to 5 days) increased plasma and brain glutamine and alanine levels. This was not associated with elevated glutamate or signs of potential glutamate-mediated cerebral injury. The increased nitrogen load should be considered in patients with renal and hepatic dysfunction. TRIAL REGISTRATION: Clinicaltrials.gov NCT02130674. Registered 5 April 2014.
Subject(s)
Alanine/administration & dosage , Brain Injuries/drug therapy , Brain Injuries/metabolism , Glutamic Acid/metabolism , Glutamine/administration & dosage , Severity of Illness Index , Adolescent , Adult , Alanine/blood , Alanine/metabolism , Brain Injuries/diagnosis , Dipeptides/administration & dosage , Dipeptides/blood , Dipeptides/metabolism , Female , Glutamic Acid/blood , Glutamine/blood , Glutamine/metabolism , Humans , Infusions, Intravenous , Male , Middle Aged , Young AdultABSTRACT
The role of oxidative stress in the initiation and progression of myelodysplastic syndromes (MDS) as a consequence of iron overload remains unclear. In this study we have simultaneously quantified plasma low-molecular-weight aminothiols, malondialdehyde, nitrite, and nitrate and have studied their correlation with serum iron/ferritin levels, patient treatment (chelation therapy), and clinical outcomes. We found significantly elevated plasma levels of total, oxidized, and reduced forms of cysteine (P < 0.001), homocysteine (P < 0.001), and cysteinylglycine (P < 0.006) and significantly depressed levels of total and oxidized forms of glutathione (P < 0.03) and nitrite (P < 0.001) in MDS patients compared to healthy donors. Moreover, total (P < 0.032) and oxidized cysteinylglycine (P = 0.029) and nitrite (P = 0.021) differed significantly between the analyzed MDS subgroups with different clinical classifications. Malondialdehyde levels in plasma correlated moderately with both serum ferritin levels (r = 0.78, P = 0.001) and serum free iron levels (r = 0.60, P = 0.001) and were significantly higher in patients with iron overload. The other analyzed compounds lacked correlation with iron overload (represented by serum iron/ferritin levels). For the first time our results have revealed significant differences in the concentrations of plasma aminothiols in MDS patients, when compared to healthy donors. We found no correlation of these parameters with iron overload and suggest the role of oxidative stress in the development of MDS disease.
Subject(s)
Iron Overload/blood , Iron Overload/complications , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/complications , Nitrates/blood , Nitrites/blood , Sulfhydryl Compounds/blood , Case-Control Studies , Dipeptides/blood , Ferritins/blood , Humans , Iron/blood , Iron Overload/pathology , Malondialdehyde/blood , Myelodysplastic Syndromes/pathology , Oxidation-Reduction , Oxidative Stress , Treatment OutcomeABSTRACT
In rats, dietary restriction of the cysteine precursor methionine suppresses hepatic stearoyl-CoA desaturase (SCD)-1 expression and activity, whereas cysteine supplementation reverses these effects. In 2 independent cohorts: Hordaland Health Study (HUSK; N=2021, aged 71-74y), Norway, and Hoorn study (N=686, aged 50-87y), Netherlands, we examined the cross-sectional associations of plasma sulfur-containing compounds (SCC; methionine, S-adenosylmethionine, S-adenosylhomocysteine, homocysteine, cystathionine, total cysteine (tCys), glutathione and cysteinylglycine) with SCD-16 index (16:1n-7/16:0), estimated from fatty acid profiles of total plasma or serum lipids. Only tCys was consistently associated with SCD-16 index after adjustments for sex and age (HUSK: partial r=0.14; Hoorn: partial r=0.11, P<0.001 for both), and after further adjustments for other SCC, body fat, diet, exercise and plasma lipids (HUSK: partial r=0.07, P=0.004; Hoorn: partial r=0.12, P=0.013). Together with animal data showing an effect of dietary cysteine on SCD1, our results suggest a role for cysteine in SCD1 regulation in humans.
Subject(s)
Amino Acids, Sulfur/blood , Diet , Stearoyl-CoA Desaturase/blood , Adipose Tissue , Aged , Aged, 80 and over , Cohort Studies , Cross-Sectional Studies , Cystathionine/blood , Cysteine/blood , Dipeptides/blood , Exercise , Fatty Acids/blood , Female , Glutathione/blood , Homocysteine/blood , Humans , Male , Methionine/blood , Middle Aged , S-Adenosylhomocysteine/blood , S-Adenosylmethionine/blood , Surveys and Questionnaires , White PeopleABSTRACT
Different low-molecular-weight thiols, including glutathione, cysteine, and cysteinylglycine are physiological free radical scavengers. On the other hand, homocysteine may play a role as an oxidant. The aim of our present study was to establish in vitro the effects of the commercial extract of Aronia melanocarpa (Aronox(®)) on the amount of selected low-molecular-weight thiols and the activity of antioxidative enzymes (superoxide dismutase, glutathione peroxidase, and glutathione reductase) in plasma obtained from patients with invasive breast cancer during different phases of treatment [before or after the surgery and patients after different phases of chemotherapy (doxorubicin and cyclophosphamide)] and from healthy subjects. Patients were hospitalized in Department of Oncological Surgery and Department of Chemotherapy, Medical University of Lodz, Poland. The level of low-molecular-weight thiols was determined by high-performance liquid chromatography. We observed that in the presence of the Aronia extract changes in amount of thiols in plasma from breast cancer patients (at all tested groups) were significantly reduced. Our results showed that tested commercial extract reduced modifications of antioxidative enzymes activity in plasma from patients during different phases of treatment, but this effect was not statistical significant. Our results suggest that the Aronia extract supplementation in breast cancer patients has a beneficial effect on thiols concentration in plasma. Plasma, as reported in this work, could be used as an experimental model to evaluate the beneficial action of plant supplements, including phenolic extracts on thiols or other molecules during different phases of treatment.
Subject(s)
Antioxidants/administration & dosage , Breast Neoplasms/blood , Carcinoma, Ductal, Breast/blood , Cysteine/blood , Dipeptides/blood , Glutathione/blood , Plant Extracts/administration & dosage , Adult , Aged , Antibiotics, Antineoplastic/therapeutic use , Antineoplastic Agents, Alkylating/therapeutic use , Breast Neoplasms/enzymology , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/enzymology , Carcinoma, Ductal, Breast/therapy , Case-Control Studies , Combined Modality Therapy , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Glutathione Peroxidase/blood , Glutathione Reductase/blood , Humans , Middle Aged , Photinia , Superoxide Dismutase/bloodABSTRACT
BACKGROUND: Nε-homocysteinyl-lysine (Nε-Hcy-Lys), a product of proteolysis of Nε-homocysteinylated proteins, has been discovered recently. We sought to investigate the presence of Nε-Hcy-Lys in patients on long-term hemodialysis (HD) and its association with markers involved in atherosclerotic vascular disease. METHODS: We studied 86 patients on long-term (median, 45 months) HD and 95 apparently healthy controls. Nε-Hcy-Lys and total homocysteine (tHcy) were assayed using high-performance liquid chromatography. Paraoxonase 1 (PON1), asymmetric dimethylarginine (ADMA), folate, 8-isoprostaglandin F2α(8-iso-PGF2α), plasminogen activator inhibitor-1 (PAI-1), C-reactive protein (CRP), together with antibodies against Nε-homocysteinylated albumin and hemoglobin, were also measured. RESULTS: Nε-Hcy-Lys was detected in 15 HD patients (17.4%). Those patients had 3.1-times lower PON1 (p<0.0001), 20% higher ADMA (p<0.0001), 30% higher PAI-1 (p<0.0001), 10% lower total cholesterol (p=0.001) and LDL-cholesterol (p<0.0001), together with 20% lower triglycerides (p<0.0001) compared with subjects without measurable Nε-Hcy-Lys. Nε-Hcy-Lys levels correlated with PON1 (r=-0.62, p<0.0001), ADMA (r=0.58, p<0.0001) and PAI-1 (r=0.59, p<0.0001). Folic acid supplementation, tHcy, folate, autoimmune response to Nε-Hcy-proteins, and oxidative stress were not associated with the presence of Nε-Hcy-Lys. PON1 is the only independent predictor of the presence of Nε-Hcy-Lys in HD patients. None of controls had measurable Nε-Hcy-Lys in serum. CONCLUSION: The presence of Nε-Hcy-Lys in HD patients is relatively infrequent and associated with lipid profile, endothelial dysfunction and impaired fibrinolysis, regardless of tHcy and folate levels.
Subject(s)
Dipeptides/blood , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/therapy , Renal Dialysis , Aged , Antibodies/blood , Arginine/analogs & derivatives , Arginine/biosynthesis , Arginine/blood , Atherosclerosis/blood , Biomarkers/blood , Dipeptides/immunology , Female , Humans , Male , Middle AgedABSTRACT
A simple, accurate and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for quantitation of bentysrepinine (Y101) in rat plasma. After the addition of diphenhydramine (internal standard, IS), plasma samples were pretreated by protein precipitation. Chromatographic separation was carried out on an Atlantis(®) analytical column (4.6 mm × 100 mm, 5 µm, Waters) with methanol: 20 mM ammonium formate consisting of 1.0% formic acid (65:35, v/v) as the mobile phase at an isocratic flow rate of 0.4 mL/min for 7.5 min. The multiple reaction monitoring (MRM) transitions were performed at m/z 490.2â339.5 for Y101 and m/z 256.0â167.0 for IS on a SCIEX API 4000 mass spectrometer in the positive ion mode with electrospray ionization (ESI) source. Good linearity was achieved over the concentration range of 1-2500 ng/mL. The intra- and inter-day precisions were less than 8.3%, and the accuracy ranged from -4.0% to 2.8%. Y101 was stable during the analysis and the storage period. The pharmacokinetic profiles of Y101 at three dose levels were successfully studied for the first time in rats by this method. After single intra-gastric administration of Y101 at the doses of 25, 50 and 100 mg/kg, C(max) and AUC(0-t) were proportional to the doses given.
Subject(s)
Antiviral Agents/blood , Benzamides/blood , Chromatography, Liquid/methods , Dipeptides/blood , Plant Extracts/blood , Tandem Mass Spectrometry/methods , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacokinetics , Benzamides/chemistry , Benzamides/pharmacokinetics , Dipeptides/chemistry , Dipeptides/pharmacokinetics , Drug Stability , Male , Plant Extracts/chemistry , Plant Extracts/pharmacokinetics , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
INTRODUCTION: LK-423 is a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity. As optimized delivery to the site of action appears crucial for further preclinical development of LK-423, the aim of this study was to perform a physicochemical and preclinical pharmacokinetic and toxicological evaluation. METHODS: The solubility, partition coefficient, permeability, and stability profile were determined. Pharmacokinetics were evaluated in rats following intravenous and oral application of LK-423, and in dogs after intravenous administration and oral administration of microcapsules, designed for colon-specific delivery of LK-423 based on pH-, time-, and enzyme-controlled release mechanisms. Additionally, the acute and subchronic toxicity was examined. RESULTS AND DISCUSSION: LK-423 is hydrophilic, sparingly to slightly soluble, and poorly permeable. Stability profile in aqueous solution is pH dependent. A pharmacokinetic study following intravenous application to rats and dogs revealed that LK-423 is rapidly eliminated with a short terminal phase half-life, and high plasma clearance, as well as a limited distribution to the peripheral tissue. Oral bioavailability of LK-423 is low, presumably due to low permeability. Debris of insoluble microcapsule coating in feces and obtained plasma concentration profiles confirm that LK-423 microcapsules are a promising approach for local treatment of inflammatory diseases of the large intestine. Acute and a subchronic toxicity results indicate that LK-423 is a safe and nontoxic drug under the applied experimental conditions.
Subject(s)
Dipeptides/chemistry , Dipeptides/pharmacokinetics , Dipeptides/toxicity , Immunologic Factors/chemistry , Immunologic Factors/pharmacokinetics , Immunologic Factors/toxicity , Phthalimides/chemistry , Phthalimides/pharmacokinetics , Phthalimides/toxicity , Administration, Oral , Animals , Capsules , Chromatography, High Pressure Liquid , Delayed-Action Preparations , Dipeptides/administration & dosage , Dipeptides/blood , Dogs , Drug Evaluation, Preclinical/methods , Drug Stability , Hydrogen-Ion Concentration , Immunologic Factors/administration & dosage , Immunologic Factors/blood , Injections, Intraperitoneal , Injections, Intravenous , Intestinal Absorption/drug effects , Intestinal Mucosa/metabolism , Male , Mass Spectrometry , Mice , Mice, Inbred Strains , Molecular Structure , Phthalimides/administration & dosage , Phthalimides/blood , Rats , Rats, Wistar , Solubility , Toxicity Tests, Acute , Toxicity Tests, ChronicABSTRACT
We previously demonstrated that beta-alanyl-branched chain amino acids have excitatory effects. Therefore, we named beta-alanyl-L-leucine, beta-alanyl-L-isoleucine and beta-alanyl-L-valine as Excitin-1, -2, and -3 , respectively. Since there is little known about the effects of Excitins, we clarified whether oral administration of Excitin-1 affects behavior in rats, alters the monoamine and amino acid levels in the central nervous system, whether Excitin-1 is incorporated into the brain, and how long it remains in the blood. Excitin-1 increased motor behavior, increasing the distance of path and number of rearings in the open field. Excitin-1 influenced some monoamine and amino acid levels in the cerebral cortex and hypothalamus. Following oral administration, Excitin-1 was detected in the cerebral cortex, hypothalamus, hippocampus and olfactory bulb. In the plasma, Excitin-1 and its metabolites beta-alanine and L-leucine were recorded. The present study demonstrated that Excitin-1 was incorporated in the brain and promoted behavioral changes in rats.
Subject(s)
Amino Acids/metabolism , Behavior, Animal/physiology , Brain/metabolism , Dipeptides/pharmacology , Administration, Oral , Alanine/administration & dosage , Alanine/blood , Alanine/pharmacology , Animals , Behavior, Animal/drug effects , Brain/drug effects , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Dipeptides/administration & dosage , Dipeptides/blood , Hypothalamus/drug effects , Hypothalamus/metabolism , Leucine/administration & dosage , Leucine/blood , Leucine/pharmacology , Motor Activity/drug effects , Motor Activity/physiology , Olfactory Bulb/drug effects , Olfactory Bulb/metabolism , RatsABSTRACT
OBJECTIVES: Patients with epilepsy have excess morbidity and mortality due to ischemic cardiovascular disease. Many of these patients have elevated concentrations of plasma total homocysteine (Hcy), which is an acknowledged risk factor for cardiovascular disease, venous thromboembolic disease, foetal malformations and dementia. Hyperhomocysteinemia may have negative effects through mechanisms involving oxidative damage. In the present study, we have investigated the aminothiol redox-status in patients on antiepileptic drugs. Thereafter, in a subset of patients with elevated total Hcy, we evaluated the effect of B-vitamin therapy. METHODS: In the first part of the study, 101 patients on antiepileptic drugs were compared with 101 matched healthy controls. The redox-species of Hcy, cysteine and cysteinylglycine, the major aminothiols in plasma, were analyzed by high-performance liquid chromatography (HPLC). Hyperhomocysteinemia was defined as fasting total Hcy above 12 micromol/L and/or post-methionine load concentrations above 38 micromol/L. In the second part of the study, 33 patients identified with hyperhomocysteinemia were supplemented with three B-vitamins for 30 days; folic acid (B9), pyridoxine (B6) and riboflavin (B2). RESULTS: All redox-species of Hcy were significantly elevated in the patients, except the fasting concentrations of reduced Hcy (p=0.09). The reduced/total ratio of cysteine in fasting plasma was lower in the patients than in the controls: 5.20% vs. 6.19%, respectively (p=0.006). After 30 days of B-vitamin supplementation, the plasma concentrations of reduced, oxidized and protein-bound Hcy species were significantly lowered by 17%, 22% and 28%, respectively. The reduced/total ratio of cysteine rose from 4.9% to 7.9% (p=0.007). CONCLUSIONS: Patients on antiepileptic drugs have abnormal aminothiol redox-status associated with hyperhomocysteinemia. This is similar to findings in patients with cardiovascular disease. B-vitamin supplementation partially corrects the abnormal aminothiol redox-status. Possibly, B-vitamin supplementation may be useful in drug-induced hyperhomocysteinemia.
Subject(s)
Anticonvulsants/adverse effects , Epilepsy/metabolism , Folic Acid/therapeutic use , Hyperhomocysteinemia/drug therapy , Pyridoxine/therapeutic use , Riboflavin/therapeutic use , Adult , Anticonvulsants/therapeutic use , Carbamazepine/adverse effects , Carbamazepine/therapeutic use , Case-Control Studies , Cysteine/blood , Dipeptides/blood , Drug Evaluation , Epilepsy/drug therapy , Female , Folic Acid/administration & dosage , Humans , Hyperhomocysteinemia/chemically induced , Liver/drug effects , Liver/enzymology , Male , Methionine , Oxidation-Reduction , Phenobarbital/adverse effects , Phenobarbital/therapeutic use , Phenytoin/adverse effects , Phenytoin/therapeutic use , Primidone/adverse effects , Primidone/therapeutic use , Pyridoxine/administration & dosage , Riboflavin/administration & dosage , Valproic Acid/adverse effects , Valproic Acid/therapeutic use , Vitamin B Deficiency/blood , Vitamin B Deficiency/chemically induced , Vitamin B Deficiency/drug therapyABSTRACT
The safety of l-alanyl-l-glutamine (l-AG) derived by fermentation using a recombinant Escherichia coli strain containing the l-amino acid alpha-ligase gene from Bacillus subtilis, was assessed in acute and subchronic toxicity studies in the rat. l-AG was tested in vitro in a bacterial reverse mutation assay and in a chromosome aberration assay. l-AG was not acutely toxic when administered to Sprague-Dawley rats by gavage at 2000mg/kg bw. In a 14-day range-finding study, l-AG at up to 5% in the diet was without effect. In the 13-week dietary study, there were no toxicologically significant differences between the treated groups (1.0, 3.0 and 5.0% l-AG) and the controls (0% and 5% l-AG produced via a different method) with respect to body weight gain, feed consumption, feed efficiency, or the results of ophthalmological, haematological, clinical chemistry, and urinalysis evaluations. Three of 10 high-dose males had mild testicular changes, however, these were of exactly the same nature and severity as those that occur spontaneously, and were considered unlikely to be treatment-related. The NOAEL in both males and females was established as the highest dose tested at 3129 and 3601mg/kg bw/day, respectively (5.0% in the diet). There was no evidence of genotoxicity of l-AG in the Ames assay or in the in vitro CHL cell chromosome aberration study.
Subject(s)
Dipeptides/toxicity , Food/toxicity , Animals , Blood Chemical Analysis , Cell Line , Chromosome Aberrations/drug effects , Cricetinae , Cricetulus , Dipeptides/analysis , Dipeptides/blood , Dose-Response Relationship, Drug , Female , Liver/drug effects , Liver/metabolism , Lung/cytology , Male , Mutagenicity Tests , Organ Size/drug effects , Pregnancy , Rats , Rats, Sprague-Dawley , Salmonella typhimurium/drug effects , Salmonella typhimurium/genetics , Sex Characteristics , Subcellular Fractions/drug effects , Subcellular Fractions/metabolismABSTRACT
OBJECTIVES: Raised plasma homocysteine is a risk factor for cardiovascular disease (CVD). Cysteine has also been associated with CVD risk. In this study, we investigated the association between known CVD risk factors, dietary factors, and total plasma cysteine, cysteinyl-glycine, and homocysteine. METHODS: The study group was 765 male workers aged between 30-49 years. The dietary habits of the subjects were recorded using a food frequency questionnaire. Body mass index (BMI), smoking status, and blood pressure were assessed, and fasting blood samples were taken for analysis of serum concentrations of vitamins, lipids, total plasma cysteine, cysteinyl-glycine, and homocysteine, and genotyping for the methylenetetrahydrofolate reductase (MTHFR) polymorphism. RESULTS: In multivariable analyses, cysteine was significantly positively associated with age and negatively associated with serum vitamin B12 and serum vitamin B6, while cysteinyl-glycine was significantly positively associated with BMI. Homocysteine (tHcy) was significantly negatively associated with serum folate, serum vitamin B12, and fruit and vegetable intake, and also depended on the MTHFR 677C>T genotype. CONCLUSIONS: Our data show a significant relationship between age, serum levels of B-vitamins and cysteine, and BMI and cysteinyl-glycine. In agreement with other studies, we also confirm an association between tHcy, serum folate and vitamin B12, MTHFR genotype, and fruit and vegetable intake. Further investigation into the role of these thiols and their determinants in CVD is required.
Subject(s)
Cardiovascular Diseases , Cysteine/blood , Dipeptides/blood , Homocysteine/blood , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Sulfhydryl Compounds/blood , Vitamin B Complex/blood , Adult , Age Factors , Blood Pressure , Body Mass Index , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Coffee/adverse effects , Cysteine/genetics , Dipeptides/genetics , Employment , Folic Acid/administration & dosage , Folic Acid/blood , Fruit , Homocysteine/genetics , Humans , Ireland , Lipids/blood , Male , Middle Aged , Risk Factors , Smoking/adverse effects , Surveys and Questionnaires , Vegetables , Vitamin B 12/administration & dosage , Vitamin B 12/blood , Vitamin B 6/administration & dosage , Vitamin B 6/blood , Vitamin B Complex/administration & dosageABSTRACT
Enhancement of depressed plasma concentrations of glutamine and arginine is associated with better clinical outcome. Supplementation of glutamine might be a way to provide the patient with glutamine, and also arginine, because glutamine provides the kidney with citrulline, from which the kidney produces arginine when plasma levels of arginine are low. The aim of the present study was to investigate the parenteral and enteral response of the administered dipeptide Ala-Gln, glutamine, citrulline and arginine. Therefore, seven patients received 20 g Ala-Gln, administered over 4 h, parenterally or enterally, on two separate occasions. Arterial blood samples were taken before and during the administration of Ala-Gln. ANOVA and a paired t test were used to test differences (P<0.05). Ala-Gln was undetectable with enteral administration, whereas Ala-Gln remained stable at a plasma concentration of 268 micromol/l throughout parenteral infusion and rapidly decreased towards zero after infusion was stopped. The highest level of glutamine was observed with parenteral infusion of the dipeptide, although enteral infusion also significantly increased plasma levels of glutamine. The highest plasma response of citrulline was observed with the enteral administration of the dipeptide, although parenteral administration also increased plasma levels of citrulline. Plasma arginine increased significantly with parenteral infusion, but not with enteral administration of Ala-Gln. In conclusion, administrations of Ala-Gln, parenteral or enteral, resulted in an increased plasma glutamine response, as compared with baseline. Interestingly, in spite of the high availability of citrulline with enteral administration of the dipeptide, only parenteral infusion of Ala-Gln increased plasma arginine concentration.